Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective

With the accumulation of scientific knowledge of the genetic causes of common diseases and continuous advancement of gene-editing technologies, gene therapies to prevent polygenic diseases may soon become possible. This study endeavored to assess population genetics consequences of such therapies. C...

Full description

Bibliographic Details
Main Author: Roman Teo Oliynyk
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/20/20/5013
id doaj-b7409ccdf68a47ad88fa3d4807c265ea
record_format Article
spelling doaj-b7409ccdf68a47ad88fa3d4807c265ea2020-11-25T02:03:01ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-10-012020501310.3390/ijms20205013ijms20205013Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics PerspectiveRoman Teo Oliynyk0Centre for Computational Evolution, University of Auckland, Auckland 1010, New ZealandWith the accumulation of scientific knowledge of the genetic causes of common diseases and continuous advancement of gene-editing technologies, gene therapies to prevent polygenic diseases may soon become possible. This study endeavored to assess population genetics consequences of such therapies. Computer simulations were used to evaluate the heterogeneity in causal alleles for polygenic diseases that could exist among geographically distinct populations. The results show that although heterogeneity would not be easily detectable by epidemiological studies following population admixture, even significant heterogeneity would not impede the outcomes of preventive gene therapies. Preventive gene therapies designed to correct causal alleles to a naturally-occurring neutral state of nucleotides would lower the prevalence of polygenic early- to middle-age-onset diseases in proportion to the decreased population relative risk attributable to the edited alleles. The outcome would manifest differently for late-onset diseases, for which the therapies would result in a delayed disease onset and decreased lifetime risk; however, the lifetime risk would increase again with prolonging population life expectancy, which is a likely consequence of such therapies. If the preventive heritable gene therapies were to be applied on a large scale, the decreasing frequency of risk alleles in populations would reduce the disease risk or delay the age of onset, even with a fraction of the population receiving such therapies. With ongoing population admixture, all groups would benefit over generations.https://www.mdpi.com/1422-0067/20/20/5013polygenic riskpolymorphismheritabilitypolygenic diseasesimulationgene therapygene editingstratificationlifetime riskadmixture
collection DOAJ
language English
format Article
sources DOAJ
author Roman Teo Oliynyk
spellingShingle Roman Teo Oliynyk
Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
International Journal of Molecular Sciences
polygenic risk
polymorphism
heritability
polygenic disease
simulation
gene therapy
gene editing
stratification
lifetime risk
admixture
author_facet Roman Teo Oliynyk
author_sort Roman Teo Oliynyk
title Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
title_short Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
title_full Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
title_fullStr Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
title_full_unstemmed Future Preventive Gene Therapy of Polygenic Diseases from a Population Genetics Perspective
title_sort future preventive gene therapy of polygenic diseases from a population genetics perspective
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-10-01
description With the accumulation of scientific knowledge of the genetic causes of common diseases and continuous advancement of gene-editing technologies, gene therapies to prevent polygenic diseases may soon become possible. This study endeavored to assess population genetics consequences of such therapies. Computer simulations were used to evaluate the heterogeneity in causal alleles for polygenic diseases that could exist among geographically distinct populations. The results show that although heterogeneity would not be easily detectable by epidemiological studies following population admixture, even significant heterogeneity would not impede the outcomes of preventive gene therapies. Preventive gene therapies designed to correct causal alleles to a naturally-occurring neutral state of nucleotides would lower the prevalence of polygenic early- to middle-age-onset diseases in proportion to the decreased population relative risk attributable to the edited alleles. The outcome would manifest differently for late-onset diseases, for which the therapies would result in a delayed disease onset and decreased lifetime risk; however, the lifetime risk would increase again with prolonging population life expectancy, which is a likely consequence of such therapies. If the preventive heritable gene therapies were to be applied on a large scale, the decreasing frequency of risk alleles in populations would reduce the disease risk or delay the age of onset, even with a fraction of the population receiving such therapies. With ongoing population admixture, all groups would benefit over generations.
topic polygenic risk
polymorphism
heritability
polygenic disease
simulation
gene therapy
gene editing
stratification
lifetime risk
admixture
url https://www.mdpi.com/1422-0067/20/20/5013
work_keys_str_mv AT romanteooliynyk futurepreventivegenetherapyofpolygenicdiseasesfromapopulationgeneticsperspective
_version_ 1724949890998468608